| Chemical Information | |
| Antiviral agent ID | DrugRepV_3611 | |
| Antiviral agent name | C-c3 Ado | |
| Structural Information | |
| 2-D Structure is not available | 3-D Structure is not available |
| Clinical Information | |
| Biological Information | |
|
Secondary Indication | Nipah virus (NiV) NA NA |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | VeroE6
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection
| |
|
Secondary Indication (Duration of drug delivery) | 10 days
| |
|
Secondary Indication (Drug concentration) | ≥8 μg/ml
| |
|
Secondary Indication (Cell based assay) | RT-PCR
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | Inhibitory concentration [ NA NA ] | |
|
Reference | Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V..Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection..Antimicrob Agents Chemother. 2006 May;50(5):1768-72. PubMed Central PMCID: PMC1472238. PMID:16641448
|  |
|
Comment | Both ribavirin and 6-aza-uridine were able to delay but not prevent Nipah virus-induced mortality. Poly(I)-poly(C12U), at 3 mg/kg of body weight daily from the day of infection to 10 days postinfection, prevented mortality in 5 of 6 infected animals.
| |